Items tagged with Pharma industry
In time for World TB Day today (March 24), an analysis has been published of research and development being carried out for tuberculosis by the 20 largest pharmaceutical companies.
GENEVA/ABUJA, 29 March 2014—African leaders and key multilateral organizations are strengthening and broadening support for local production of essential medicines on the continent. The Seventh Joint African Union (AU) Conference of Ministers of Economy and Finance and the Economic Commission for Africa (ECA) Conference of African Ministers of Finance, Planning and Economic Development is being held in Abuja, Nigeria from 25-30 March.
Three major pharmaceutical companies - AstraZeneca, Johnson & Johnson and Pfizer - have recently delayed or canceled clinical trials for testing tuberculosis (TB) drugs in India and South Africa. Activists say this is symbolic of a trend by Big Pharma to abandon research into diseases that affect poor people.
Top officials meet amid apprehension of sanctions under US law; decide to take Washington to the World Trade Organization if such action taken
BASEL — Students from around the world are gathering momentum to challenge their universities’ licensing policies and research and development systems. That was one of the messages emerging from the annual meeting of Universities Allied for Essential Medicines (UAEM) Europe.
The drugs don't work - and neither does the market, when it comes to antibiotics.
A nasty spat has broken out between the generic pharmaceutical industry and an international organization that develops widely accepted standards for developing prescription drugs.
No treatment Ebola, high prices for hepatitis C drugs: Time to change the pharmaceutical research system (post)
The high state of anxiety about the Ebola virus and its possible spread throughout Africa has caused fear in the world. Effective vaccines and medicines to prevent and treat Ebola do not yet exist. There are too few cases to make it profitable for pharmaceutical companies to invest in research and development (R&D), and at the end of the day those who are at risk are too poor to pay high prices.
In 2000, the international aid organization Doctors Without Borders launched small HIV/AIDS treatment projects in Thailand, South Africa and Cameroon. At the time, the cost of treating one person with anti-retroviral drugs was about $10,000 a year, posing a significant challenge for humanitarian groups fighting HIV/AIDS in developing countries.
The current income-based grouping of countries needs to be changed or access to medicines in middle-income countries will worsen, several speakers said yesterday at a joint meeting between three international organisations on health, trade, and intellectual property. But middle-income countries should step up their engagement in organisations such as the World Health Organization, according to WHO and civil society.
Page 2 of 8 · Total posts: 0←First 1 2 3 Last→